Toni K. Choueiri, MD
The 2018 ASCO Annual Meeting included a number of clinical highlights in renal cell carcinoma (RCC), according to Toni K. Choueiri, MD. On the heels of multiple FDA approvals throughout the latter half of 2017 and the beginning of 2018, the field continues to rapidly shift.
Choueiri, director of the Kidney Cancer Center at Dana-Farber Cancer Institute, recapped some of the most significant data presented thus far in 2018 for the treatment of patients with RCC.
OncLive: Can you reflect on the CARMENA trial that was presented at the 2018 ASCO Annual Meeting?
It was a big conference for kidney cancer; we had a presentation that made it to the plenary session, [which was] CARMENA. This study asked the question of VEGF-targeted therapy in the modern setting, namely sunitinib, and whether taking the kidney out in metastatic RCC by cytoreductive nephrectomy makes sense. What was presented in the past in the cytokine era, as well as the many retrospective studies, was that cytoreductive nephrectomy helps.
... to read the full story